|16:31 EDT||DEPO||Depomed files patent infringement suit against Purdue Pharma|
Depomed disclosed in a regulatory filing that on January 29, Depomed filed a complaint in the United States District Court for the District of New Jersey against Purdue Pharma and affiliated companies for infringement of U.S. Patent Nos. 6,340,475; 6,635,280; and 6,723,340. The complaint alleges infringement of the Depomed patents arising from Purdue’s commercialization of OxyContin in the United States. The Depomed patents relate to Depomed’s Acuform drug delivery technology. U.S. Patent Nos. 6,340,475 and 6,635,280 will expire in 2016, and U.S. Patent No. 6,723,340 will expire in 2021.